Boehringer Ingelheim’s survodutide phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing ...
During pregnancy, maternal glucose management was excellent in both groups, with CGM time-in-range above 90% for each arm.
Evidence-Based Diabetes Management | Journals | The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results